Published in JAMA Neurol on November 01, 2013
Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry (2015) 1.09
Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med (2015) 0.94
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther (2014) 0.94
Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. Am J Med Genet A (2015) 0.91
Structural variation and the expanding genomic architecture of Parkinson disease. JAMA Neurol (2013) 0.89
22q11.2 deletion syndrome. Nat Rev Dis Prim (2015) 0.87
Acute Dystonia in a Patient with 22q11.2 Deletion Syndrome. Ment Illn (2015) 0.85
Whole-Genome Sequencing Suggests Schizophrenia Risk Mechanisms in Humans with 22q11.2 Deletion Syndrome. G3 (Bethesda) (2015) 0.85
Comparative mapping of the 22q11.2 deletion region and the potential of simple model organisms. J Neurodev Disord (2015) 0.81
22q11 deletion syndrome: current perspective. Appl Clin Genet (2015) 0.81
Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurol (2016) 0.77
Glutamatergic markers, age, intellectual functioning and psychosis in 22q11 deletion syndrome. Psychopharmacology (Berl) (2015) 0.77
Neuropsychiatric aspects of 22q11.2 deletion syndrome: considerations in the prenatal setting. Prenat Diagn (2016) 0.75
Proteomics in immunity and herpes simplex encephalitis. Expert Rev Proteomics (2013) 0.75
Copy number variability in Parkinson's disease: assembling the puzzle through a systems biology approach. Hum Genet (2016) 0.75
Chromosome 22q11.2 deletion may contain a locus for recessive early-onset Parkinson's disease. Parkinsonism Relat Disord (2014) 0.75
Autism spectrum disorder in adults: diagnosis, management, and health services development. Neuropsychiatr Dis Treat (2016) 0.75
New Genes Causing Hereditary Parkinson's Disease or Parkinsonism. Curr Neurol Neurosci Rep (2017) 0.75
Genomic Disorders in Psychiatry-What Does the Clinician Need to Know? Curr Psychiatry Rep (2017) 0.75
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform (2011) 8.50
The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain (1999) 5.13
Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A (2000) 4.83
Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet (2008) 3.76
Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol (2011) 3.45
Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A (2005) 3.13
Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum Mol Genet (2008) 2.76
Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr (2011) 2.57
A population study of chromosome 22q11 deletions in infancy. Arch Dis Child (1998) 2.15
Diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in a mouse model of 22q11 deletion/DiGeorge syndrome. Proc Natl Acad Sci U S A (2009) 2.04
The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome. Am J Med Genet A (2009) 1.82
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol (2005) 1.60
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol (2010) 1.56
The genetics and neuropathology of Parkinson's disease. Acta Neuropathol (2012) 1.56
LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology (2005) 1.56
Genomewide SNP assay reveals mutations underlying Parkinson disease. Hum Mutat (2008) 1.49
Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology (2012) 1.44
A comprehensive analysis of 22q11 gene expression in the developing and adult brain. Proc Natl Acad Sci U S A (2003) 1.42
Premature death in adults with 22q11.2 deletion syndrome. J Med Genet (2009) 1.42
Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. Mov Disord (2009) 1.36
Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J Psychiatr Res (2010) 1.30
Neuropathologic features in adults with 22q11.2 deletion syndrome. Cereb Cortex (2008) 1.19
The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain (2011) 1.16
Extracardiac features predicting 22q11.2 deletion syndrome in adult congenital heart disease. Int J Cardiol (2008) 1.12
Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol (1998) 1.10
Age-dependent microRNA control of synaptic plasticity in 22q11 deletion syndrome and schizophrenia. J Neurosci (2012) 1.07
Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes. Mol Cell Neurosci (2008) 1.06
A rare novel deletion of the tyrosine hydroxylase gene in Parkinson disease. Hum Mutat (2010) 1.04
Childhood-onset schizophrenia associated with parkinsonism in a patient with a microdeletion of chromosome 22. Mayo Clin Proc (1998) 1.02
Copy number variation in familial Parkinson disease. PLoS One (2011) 1.02
Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr Bull (2012) 0.97
Co-occurrence of early-onset Parkinson disease and 22q11.2 deletion syndrome: Potential role for dopamine transporter imaging. Am J Med Genet A (2010) 0.97
miRNA-mediated risk for schizophrenia in 22q11.2 deletion syndrome. Front Genet (2012) 0.96
The neuropathological effects of antipsychotic drugs. Schizophr Res (1999) 0.87
An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother (2011) 0.85
The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat Disord (2003) 0.79
Comparative genome hybridization array analysis for sporadic Parkinson's disease. Int J Neurosci (2008) 0.78
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res (2007) 10.08
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet (2003) 6.63
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Ultrasound-guided popliteal block through a common paraneural sheath versus conventional injection: a prospective, randomized, double-blind study. Reg Anesth Pain Med (2013) 3.37
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A (2005) 3.13
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry (2003) 3.04
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet (2008) 2.84
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Copy number variations and risk for schizophrenia in 22q11.2 deletion syndrome. Hum Mol Genet (2008) 2.76
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet (2010) 2.70
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature (2006) 2.56
Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Hum Pathol (2009) 2.54
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem (2005) 2.26
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol (2007) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry (2014) 2.15
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology (2012) 2.06
A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics (2005) 2.04
Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol (2008) 2.03
Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. Am J Med Genet A (2005) 2.03
Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep (2008) 2.02
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
SORCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol (2011) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am J Hum Genet (2013) 1.97
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res (2006) 1.89
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain (2006) 1.86
Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry (2009) 1.85
The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol (2005) 1.83
The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome. Am J Med Genet A (2009) 1.82
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
A major susceptibility locus for specific language impairment is located on 13q21. Am J Hum Genet (2002) 1.79
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Intracranial aneurysms: from vessel wall pathology to therapeutic approach. Nat Rev Neurol (2011) 1.77
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging (2008) 1.76
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome. Biol Psychiatry (2007) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62